Susan L. Ford

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study”.

Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The Lancet HIV(2024)10.1016/s2352-3018(23)00300-4

N/A

1.1DataRank · unranked

29 citations

Edmund V. Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A. Marzinke, Cynthia McCoig +36 more

Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial

The Lancet HIV(2023)10.1016/s2352-3018(23)00200-x

N/A

0.580DataRank · unranked

14 citations

Brett Hanscom, Zhe Wang, Steven A. Safren, Christina Psaros, Deborah Donnell +61 more

Safety of combined long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study

The Lancet HIV(2025)10.1016/s2352-3018(24)00344-8

N/A

0.535DataRank · unranked

12 citations

Kristin Baltrusaitis, Brookie M. Best, Jack Moye, Ellen Townley, Avy Violari +36 more

Pharmacologic evaluation of delayed long-acting cabotegravir administration among cisgender women in HPTN 084

Antimicrobial Agents and Chemotherapy(2024)10.1128/aac.00994-24

N/A

0.165DataRank · unranked

2 citations

Kelong Han, Brett Hanscom, Xu Guo, Estelle Piwowar-Manning, Craig W. Hendrix +14 more

Evaluation of long‐acting cabotegravir safety and pharmacokinetics in pregnant women in eastern and southern Africa: a secondary analysis of HPTN 084

Journal of the International AIDS Society(2025)10.1002/jia2.26401

N/A

0DataRank · unranked

17 citations

Brett Hanscom, Xu Guo, Clemensia Nkabiito, Patricia Mandima, Patricia Ntege Nahirya +17 more

Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial

UNC Libraries(2025)10.17615/9zee-gb05

N/A

0DataRank · unranked

0 citations

Beatriz Grinsztejn, Mark A. Marzinke, Brett Hanscom, Alex R. Rinehart, Susan H. Eshleman +26 more

Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084

The Journal of Infectious Diseases(2021)10.1093/infdis/jiab576

N/A

0DataRank · unranked

69 citations

Jessica M. Fogel, Estelle Piwowar‐Manning, Gordon Chau, Vanessa Cummings, Yaw Agyei +28 more

Evaluation of pharmacokinetic interactions between long‐acting cabotegravir or emtricitabine/tenofovir disoproxil fumarate and hormonal contraceptive agents: a tertiary analysis of South African participants in HPTN 084

Journal of the International AIDS Society(2025)10.1002/jia2.70056

N/A

0DataRank · unranked

0 citations

Brett Hanscom, Daniel Haines, Kimberly K. Scarsi, Yaw Agyei, Estelle Piwowar‐Manning +17 more

A population pharmacokinetic model based on HPTN 077 of long‐acting injectable cabotegravir for HIV PrEP

British Journal of Clinical Pharmacology(2022)10.1111/bcp.15477

N/A

0DataRank · unranked

11 citations

Kristin L. Bigos, Mark A. Marzinke, Raphael J. Landovitz, Marybeth McCauley, Susan L. Ford +5 more

Long-Acting Cabotegravir and Rilpivirine Dosed Every 2 Months in Adults With Human Immunodeficiency Virus 1 Type 1 Infection: 152-Week Results From ATLAS-2M, a Randomized, Open-Label, Phase 3b, Noninferiority Study

Clinical Infectious Diseases(2023)10.1093/cid/ciad020

N/A

0DataRank · unranked

128 citations

Gary Richmond, Giuliano Rizzardini, Anders Thalme, Pierre‐Marie Girard, Alexander Wong +20 more

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083

Antimicrobial Agents and Chemotherapy(2023)10.1128/aac.00053-23

N/A

0DataRank · unranked

29 citations

Jessica M. Fogel, Zhe Wang, Estelle Piwowar‐Manning, Ryan Kofron, Amber Moser +24 more